195 related articles for article (PubMed ID: 25810244)
1. Immunocytochemical analysis of p63 and 34βE12 in fine needle aspiration cytology specimens for breast lesions: a potentially useful discriminatory marker between intraductal papilloma and ductal carcinoma in situ.
Hoshikawa S; Sano T; Hirato J; Oyama T; Fukuda T
Cytopathology; 2016 Apr; 27(2):108-14. PubMed ID: 25810244
[TBL] [Abstract][Full Text] [Related]
2. Availability of immunocytochemistry using cocktail antibody targeting p63/cytokeratin14 for the differential diagnosis of fibroadenoma and ductal carcinoma in situ in fine needle aspiration cytology of the breast.
Maeda I; Oana Y; Tsugawa K; Takagi M
Cytopathology; 2017 Oct; 28(5):378-384. PubMed ID: 28685877
[TBL] [Abstract][Full Text] [Related]
3. Usefulness of immunocytochemistry using a Breast Marker antibody cocktail targeting P63/cytokeratin7/18/cytokeratin5/14 for fine needle aspiration of the breast: a retrospective cohort study of 139 cases.
Tanaka S; Kanomata N; Teramura K; Wakita K; Kunihisa T; Yano Y; Moriya T; Hayashi Y
Cytopathology; 2016 Dec; 27(6):465-471. PubMed ID: 27060708
[TBL] [Abstract][Full Text] [Related]
4. [The diagnostic value of 34 betaE 12 in differential diagnosis of benign and malignant mammary lesions].
Di F; Wong NL
Zhonghua Bing Li Xue Za Zhi; 2004 Feb; 33(1):31-5. PubMed ID: 14989925
[TBL] [Abstract][Full Text] [Related]
5. p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
J Clin Pathol; 2002 Dec; 55(12):936-9. PubMed ID: 12461063
[TBL] [Abstract][Full Text] [Related]
6. [Role of immunocytochemistry in fine needle aspiration cytology diagnosis of mammary lesions of breast].
Di F; Wong NL
Zhonghua Bing Li Xue Za Zhi; 2006 Dec; 35(12):738-43. PubMed ID: 17374259
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ?
Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM
Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086
[TBL] [Abstract][Full Text] [Related]
8. Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ.
Furuya C; Kawano H; Yamanouchi T; Oga A; Ueda J; Takahashi M
Pathol Int; 2012 Jun; 62(6):381-90. PubMed ID: 22612506
[TBL] [Abstract][Full Text] [Related]
9. The significance of extracellular mucin in breast fine needle aspiration specimens.
Shield PW; Ribu DL; Cominos D
Cytopathology; 2016 Jun; 27(3):185-92. PubMed ID: 26104545
[TBL] [Abstract][Full Text] [Related]
10. The Role of P63 Immunocytochemistry for Myoepithelial Cells in the Diagnosis of Atypical and Suspicious Cases in Breast Fine Needle Aspiration Cytology (FNAC).
Hafez NH; Tahoun NS
J Egypt Natl Canc Inst; 2010 Jun; 22(2):123-34. PubMed ID: 21860469
[TBL] [Abstract][Full Text] [Related]
11. p63 Immunocytochemistry improves accuracy of diagnosis with fine-needle aspiration of the breast.
Harton AM; Wang HH; Schnitt SJ; Jacobs TW
Am J Clin Pathol; 2007 Jul; 128(1):80-5. PubMed ID: 17580273
[TBL] [Abstract][Full Text] [Related]
12. [Fine needle aspiration cytology diagnosis of ductal lesions of breast].
Di F; Wong NL
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):467-72. PubMed ID: 21055176
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of CD56 and CD57 immunostainings for discrimination between endocrine ductal carcinoma in situ and intraductal papilloma.
Tajima S; Maeda I; Kanemaki Y; Nakajima Y; Tatsunami S; Fukuda M; Takagi M
Pathol Int; 2010 Jun; 60(6):459-65. PubMed ID: 20518901
[TBL] [Abstract][Full Text] [Related]
14. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples.
Reis-Filho JS; Milanezi F; Amendoeira I; Albergaria A; Schmitt FC
Cancer; 2003 Jun; 99(3):172-9. PubMed ID: 12811858
[TBL] [Abstract][Full Text] [Related]
15. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations.
Moinfar F; Man YG; Lininger RA; Bodian C; Tavassoli FA
Am J Surg Pathol; 1999 Sep; 23(9):1048-58. PubMed ID: 10478664
[TBL] [Abstract][Full Text] [Related]
16. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
[TBL] [Abstract][Full Text] [Related]
17. Nipple aspirate fluid cytology in breast carcinoma.
Krishnamurthy S; Sneige N; Thompson PA; Marcy SM; Singletary SE; Cristofanilli M; Hunt KK; Kuerer HM
Cancer; 2003 Apr; 99(2):97-104. PubMed ID: 12704689
[TBL] [Abstract][Full Text] [Related]
18. Expression of p63 immunostaining in liquid-based cytology (BD SurePath) of breast fine-needle aspiration.
Osugi M; Kinoshita K; Sugita A; Kito K; Maeda T
Diagn Cytopathol; 2018 Oct; 46(10):845-852. PubMed ID: 30043485
[TBL] [Abstract][Full Text] [Related]
19. [Role of cytokeratin expression in differential diagnosis of intraductal proliferative lesions of breast].
Zhang JL; Zhang HY; Wei B; Lang ZQ; Bu H
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):316-9. PubMed ID: 15363314
[TBL] [Abstract][Full Text] [Related]
20. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis.
Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M
Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
